CAM
RGNX icon

ClariVest Asset Management’s Regenxbio RGNX Stock Holding History

ClariVest Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$234 Hold
20
– – ﹤0.01% 838
2024
Q2 		$234 Hold
20
– – ﹤0.01% 838
2024
Q1 		$421 Hold
20
– – ﹤0.01% 812
2023
Q4 		$359 Hold
20
– – ﹤0.01% 853
2023
Q3 		$0 Sell
20
-37
-65% -$671 ﹤0.01% 832
2023
Q2 		$1K Sell
57
-15,088
-100% -$291K ﹤0.01% 632
2023
Q1 		$287K Buy
15,145
+43
+0.3% +$951 0.01% 414
2022
Q4 		$342K Sell
15,102
-24
-0.2% -$543 0.02% 408
2022
Q3 		$400K Sell
15,126
-42
-0.3% -$1.25K 0.02% 389
2022
Q2 		$375K Hold
15,168
– – 0.02% 413
2022
Q1 		$504K Buy
15,168
+5,818
+62% +$162K 0.02% 383
2021
Q4 		$305K Sell
9,350
-617
-6% -$21K 0.01% 466
2021
Q3 		$418K Sell
9,967
-344
-3% -$12.4K 0.01% 453
2021
Q2 		$400K Buy
10,311
+24
+0.2% +$858 0.01% 449
2021
Q1 		$351K Sell
10,287
-600
-6% -$25.6K 0.01% 454
2020
Q4 		$493K Sell
10,887
-14,860
-58% -$519K 0.02% 386
2020
Q3 		$709K Sell
25,747
-1,160
-4% -$37.8K 0.02% 328
2020
Q2 		$992K Sell
26,907
-717
-3% -$26.7K 0.03% 322
2020
Q1 		$894K Buy
27,624
+57
+0.2% +$2.38K 0.03% 321
2019
Q4 		$1.13M Sell
27,567
-18,333
-40% -$724K 0.03% 339
2019
Q3 		$1.64M Sell
45,900
-600
-1% -$24.3K 0.04% 279
2019
Q2 		$2.39M Sell
46,500
-300
-0.6% -$15K 0.05% 231
2019
Q1 		$2.68M Sell
46,800
-3,362
-7% -$167K 0.05% 280
2018
Q4 		$2.1M Buy
50,162
+19,381
+63% +$1.14M 0.05% 297
2018
Q3 		$2.32M Sell
30,781
-819
-3% -$59K 0.04% 304
2018
Q2 		$2.26M Buy
+31,600
New +$1.51M 0.04% 326
2018
Q1 		– Sell
-33,100
Closed -$1.1M – 764
2017
Q4 		$1.1M Buy
+33,100
New +$997K 0.02% 414

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ClariVest Asset Management's RGNX Position: Q3 2024 in Review

ClariVest Asset Management held its Regenxbio (RGNX) position steady in Q3 2024 at 20 shares worth $234. The position accounts for ﹤0.01% of the portfolio, ranked #838.

ClariVest Asset Management first reported a position in RGNX in Q4 2017 and has held it in 27 quarters since. The position peaked at $2.68M in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

  • ClariVest Asset Management held 20 shares of Regenxbio worth $234 as of Q3 2024.
  • ClariVest Asset Management left its Regenxbio share count unchanged in Q3 2024.
  • Regenxbio made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #838 holding.
  • ClariVest Asset Management first reported a position in Regenxbio in Q4 2017 and has held it in 27 quarters since.
  • ClariVest Asset Management's Regenxbio position peaked at $2.68M in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.